|
Biomarker subgroup
|
Patients n (%a)
|
|---|
|
HER2 mRNA and PI3K status available (N = 951)
|
HER2 mRNA level
|
PI3K mutation status
| |
|
≤median (n = 484)
|
Mutated
|
171 (35.3)
|
| |
Non-mutated
|
313 (64.7)
|
|
>median (n = 467)
|
Mutated
|
86 (18.4)
|
| |
Non-mutated
|
381 (81.6)
|
|
HER2 mRNA and HER2 IHC expression available (N = 989)
|
HER2 mRNA level
|
HER2 IHC expression
| |
|
≤median (n = 495)
|
Focal/heterogeneous
|
114 (23.0)
|
| |
Homogeneous
|
381 (77.0)
|
|
>median (n = 494)
|
Focal/heterogeneous
|
19 (3.8)
|
| |
Homogeneous
|
475 (86.6)
|
|
PI3K mutation status and HER2 IHC expression available (N = 976)
|
HER2 IHC expression
|
PI3K mutation status
| |
|
Focal/heterogeneous (n = 136)
|
Mutated
|
57 (41.9)
|
| |
Non-mutated
|
79 (58.1)
|
|
Homogeneous (n = 840)
|
Mutated
|
202 (24.0)
|
| |
Non-mutated
|
638 (76.0)
|
- aPercentage based on number of patients with both biomarkers available and calculated within subgroups. HER2 mRNA missing n = 96; PI3K mutation status missing n = 109; IHC H score missing n = 10
- HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, PI3K phosphoinositide 3-kinase
